PURPOSEThe use of bevacizumab in glioblastoma has been associated with increased progression-free survival and improvement in symptoms and quality of life. There are no clinical indicators on how to ...

Early and intensive treatment of age-related macular degeneration with bevacizumab is associated with greater long-term improvements in visual acuity than are ranibizumab or aflibercept, a real ...

Bevacizumab was administered at a dose of 10 mg per kilogram of body weight intravenously every 2 weeks, and erlotinib was administered at a dose of 150 mg orally once daily during each 28-day cycle.

The most common TRAEs of any grade were acneiform rash (93%), diarrhea (89%), proteinuria (78%), and dry skin (64%).

First-line treatment with alectinib and bevacizumab appears to be effective for patients with ALK-rearranged, metastatic NSCLC, according to researchers.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)2.8 million injections of repackaged ...

The global Ophthalmology Drugs Market , valued at US$18.34 billion in 2024 stood at US$19.52 billion in 2025 and is projected ...

EGFR amplification was more frequent in patients who received bevacizumab for ≤6 months (46% v 20%). Multivariate analysis showed that CDK4 amplification was associated with longer time on bevacizumab ...